The Jain Foundation

The Jain Foundation is an organization dedicated to addressing muscular dystrophies resulting from dysferlin protein deficiency. It focuses on supporting drug development and clinical trials aimed at finding effective treatments for these conditions. In addition to its research initiatives, the foundation has established a robust patient support and advocacy platform, ensuring that affected individuals and families have access to necessary resources and information. Through its comprehensive approach, the Jain Foundation aims to advance scientific understanding and improve the quality of life for those impacted by muscular dystrophies.

http://www.jain-foundation.org

https://crunchbase.com/organization/jain-foundation

https://facebook.com/jainfoundation

https://linkedin.com/company/jain-foundation-inc

https://pitchbook.com/profiles/investor/223012-63

https://twitter.com/jainfoundation

Douglas Albrecht

Co-President

1 past transactions

Myonexus Therapeutics

Seed Round in 2017

Myonexus Therapeutics is a clinical-stage company focused on developing gene therapies for rare diseases, specifically targeting Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C. The company's innovative treatments are based on research conducted at Nationwide Children’s Hospital, which is recognized for its leadership in muscular dystrophy gene therapy discovery and translational research. In addition to LGMD, Myonexus is also engaged in developing therapies for other conditions, including Charcot-Marie-Tooth disease and various CNS-related disorders, utilizing advancements in precision genetic medicine to address unmet medical needs in these areas.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.